Icatibant Axiromed

Icatibant, the active ingredient in Icatibant Axiromed, is a bradykinin B2 receptor antagonist presented as an injection solution for subcutaneous use. It is indicated for the treatment of hereditary angioedema attacks in patients with a confirmed diagnosis and helps reduce swelling, pain and the risk of airway obstruction.

GNH USA supplies Icatibant Axiromed as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing and regulatory support for global healthcare providers.

Icatibant is a targeted therapy for hereditary angioedema, acting on the bradykinin pathway to control acute swelling.

Hereditary angioedema (HAE) attacks: rapid reduction of swelling and prevention of airway compromise.

Icatibant may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Injection site pain: discomfort at the subcutaneous injection site. - Redness or swelling at injection site: localized inflammatory response. - Nausea: mild gastrointestinal upset. - Headache: transient cranial discomfort. - Dizziness: brief sensation of light‑headedness. - Fatigue: temporary feeling of tiredness.

Serious or Rare Side Effects: - Hypersensitivity reaction: rash, urticaria or bronchospasm. - Anaphylaxis: severe, potentially life‑threatening allergic response. - Severe hypotension: marked drop in blood pressure. - Paradoxical angioedema: worsening swelling despite therapy. - Injection‑site infection: signs of local infection requiring medical attention.

Before using Icatibant, consider the following safety measures.

Pregnancy: safety not established; avoid unless benefit outweighs risk. Breastfeeding: unknown safety; weigh potential risks. Renal impairment: use with caution; monitor renal function. Concomitant ACE inhibitors: monitor for increased bradykinin‑related effects. Known hypersensitivity: do not use in patients with documented allergy to icatibant. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Icatibant may interact with other medicines that influence the bradykinin system or vascular tone.

Major Interactions (Avoid): - ACE inhibitors: may increase bradykinin levels and exacerbate angioedema. - Other bradykinin B2 receptor antagonists: concurrent use can reduce therapeutic effectiveness.

Moderate Interactions (Monitor Closely): - Estrogen‑containing contraceptives: may increase frequency of HAE attacks. - NSAIDs: can aggravate angioedema symptoms. - DPP‑4 inhibitors: potential additive effect on bradykinin pathways. - C1‑esterase inhibitor prophylaxis: monitor for overlapping efficacy.